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Abstract 
Introduction: There have been no reports about predicting survival of patients with 
advanced cancer constructed entirely with objective variables. We aimed to develop a 
prognostic model based on laboratory findings and vital signs using a fractional 
polynomials (FP) model. 
Methods: A multicenter prospective cohort study was conducted at 58 specialist 
palliative care services in Japan from September 2012 to April 2014. Eligible patients 
were > 20 years old and had advanced cancer. We developed models for predicting 7-day, 
14-day, 30-day, 56-day, and 90-day survival by using the FP modelling method. 
Results: Data from 1039 patients were analyzed to develop each prognostic model 
(Objective Prognostic Index for advanced cancer: OPI-AC). All models included the heart 
rate, urea, and albumin, while some models included the respiratory rate, creatinine, C-
reactive protein, lymphocyte count, neutrophil count, total bilirubin, lactate 
dehydrogenase, and platelet / lymphocyte ratio. The area under the curve was 0.77, 0.81, 
0.90, 0.90, and 0.92 for the 7-day, 14-day, 30-day, 56-day, and 90-day model, respectively. 
The accuracy of the OPI-AC predicting 30-day, 56-day, and 90-day survival was 
significantly higher than that of the Palliative Prognostic Score or the Prognosis in 
Palliative Care Study model, which are based on a combination of symptoms and 
physician estimation. 
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Conclusion: We developed highly accurate prognostic indexes for predicting the survival 
of patients with advanced cancer from objective variables alone, which may be useful for 
end-of-life management. The FP modelling method could be promising for developing 
other prognostic models in future research. 
 
Keywords: prognostic index, laboratory findings, vital signs, fractional polynomials 
model 
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Introduction 
For patients with life-threatening illnesses such as advanced cancer, accurate 
prognostic information is essential to provide the opportunity for patients, family 
members, and clinicians to engage in open discussion about advance care planning[1–3]. 
Several validated prognostic tools have been developed to predict the survival of 
patients with advanced cancer[4], including the Palliative Prognostic Index (PPI)[5], 
Palliative Prognostic Score (PaP score)[6], and Prognosis in Palliative Care Study 
(PiPS)[7]. These have acceptable predictive accuracy with area under the curve (AUC) 
values of 0.62-0.86[7,8], but a major limitation is use of subjective variables, such as the 
patient’s symptoms and condition (e.g., performance status) and the physician’s 
prediction of survival[9–11]. Recent studies have revealed that such subjective variables 
are influenced by the evaluator’s experience and competence[11,12]. Therefore, more 
extensive use of objective variables, such as laboratory findings and vital signs, has been 
strongly recommended when developing prognostic models[13–17].  
Furthermore, the existing prediction tools are based on routine statistical methods such 
as regression analysis, but the guidelines for transparent reporting of a multivariable 
model for individual prognosis or diagnosis (TRIPOD statement) recommend the 
fractional polynomials (FP) modelling method as one of the ideal approaches for 
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developing a multivariable prediction model[18]. 
To our best knowledge, there are currently only 2 prognostic models that are entirely 
composed of objective variables, which are the Objective Palliative Prognostic Score 
(OPPS) and the set of six adaptable prognosis prediction (SAP) models[19,20]. The OPPS 
predicts 7-day survival by using 6 variables (heart rate, white blood cell count, platelet 
count, creatinine, potassium, and history of chemotherapy) and has an AUC of 0.82[19]. 
The SAP models predict survival for 1–6 months by using 3 variables (neutrophil count, 
lactate dehydrogenase, and albumin), with AUC values ranging from 0.71 to 0.85[20]. 
Although these models suggest that exclusive use of objective parameters may allow 
successful prediction of survival, several major limitations should be noted: development 
from a small patient sample, no validation study, limited or varied target time span, and 
lack of advanced statistical methods. 
Therefore, we decided to explore the accuracy of a prognostic index that only 
incorporated objective parameters (laboratory findings and vital signs) and was based 
on the FP modelling method. We wanted to obtain insights into the predictability of 
patient survival using only objective parameters and the variables that would be 
effective for prediction of short-term to long-term survival. Accordingly, this study was 
performed to develop prognostic models for prediction of short-term to long-term survival 
9 
using only objective parameters and the FP modelling method.   
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Material and Methods 
This study was a secondary analysis of the Japan-prognostic assessment tools validation 
(J-ProVal) study, which was a multicentre prospective cohort study performed to 
investigate the feasibility and accuracy of existing prognostic tools[21]. It was conducted 
at 58 palliative care services in Japan from September 2012 through April 2014. The 
participating services included 19 hospital palliative care teams, 16 palliative care units, 
and 23 home-based palliative care services. The primary physician of each patient 
performed evaluation and recorded demographic and clinical characteristics of the 
participants. Data from laboratory tests were only obtained if the patient underwent 
blood tests as a clinical necessity within 1 week after enrolment. 
 
This study was conducted in accordance with the ethical standards of the Helsinki 
Declaration and the ethical guidelines for epidemiological research presented by the 
Ministry of Health, Labour and Welfare of Japan. The Institutional Review Boards of all 
participating services approved this study. 
 
Patients 
Eligible patients were enrolled consecutively as they were referred to the participating 
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services during the study period. All services were asked to evaluate and collect data on 
a specific number of patients, ranging from 20 to 100, based on the size of the service. 
Patients were eligible for the study if they were adults (aged 20 years or older) with 
locally advanced or metastatic cancer (including hematopoietic neoplasms) who had been 
admitted to a palliative care unit, referred to a hospital palliative care team, or were 
receiving home-based palliative care.  
 
Outcome 
We used the FP method to develop prognostic models based on laboratory findings and 
vital signs for predicting the 7-day, 14-day, 30-day, 56-day, and 90-day survival of 
patients with advanced cancer (Objective Prognostic Index for advanced cancer: OPI-AC). 
 
Measurements and Variables 
The physician assessed variables on the day of admission, including the patient’s age, 
gender, site of the primary tumor and metastases, anticancer treatment during the 1-
month period before assessment (i.e., chemotherapy, hormone therapy, or radiotherapy), 
symptoms and general condition, vital signs (heart rate and respiratory rate), and the 
results of blood tests performed during the 1-week period before assessment. The 
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following laboratory tests were assessed: leukocyte count (109/L), neutrophil count 
(109/L), lymphocyte count (109/L), platelet count (109/L), urea (mg/dL), creatinine (mg/dL), 
alanine transaminase (U/L), alkaline phosphatase (U/L), total bilirubin (mg/dL), lactate 
dehydrogenase (U/L), albumin (g/dL), and C reactive protein (mg/dL). Physicians 
followed the patients until death or 6 months after enrolment. 
We used the heart rate and respiratory rate on the day of admission and the laboratory 
data obtained during the 1-week period before assessment as objective variables. We also 
added 3 composite variables, which were the neutrophil / lymphocyte ratio (NLR)[22], 
Prognostic Nutritional Index (PNI)[23], and platelet / lymphocyte ratio (PLR)[24]. Thus, 
a total of 17 variables were considered for the prognostic models. 
 
Modified PiPS-B14/56  
The modified PiPS-B14/56 can identify patients with an expected survival of days (0-13 
days) or weeks (14-55 days), respectively. Scores were calculated from the following 
variables: symptoms (presence or absence of anorexia, dyspnoea, dysphagia, fatigue, and 
weight loss during the last month); Eastern Cooperative Oncology Group performance 
status; global health status (1 = extremely poor health, 7 = normal health); cognitive 
status assessed according to the Abbreviated Mental Test score; pulse rate; and 
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laboratory data (leukocyte count, neutrophil count, lymphocyte count, platelet count, 
urea, creatinine, alanine aminotransferase, alkaline phosphatase, total bilirubin, lactate 
dehydrogenase, albumin, and C-reactive protein). Cognitive status was evaluated 
according to the Abbreviated Mental Test score by physician proxy, and was rated as zero 
if the score was  3 points[7,21]. 
 
PaP score 
PaP scores were used to classify patients into three groups according to the probability 
of 30-day survival: group A >70%, group B 30–70%, and group C <30%[6]. PaP scores 
were calculated from the following variables: symptoms (presence or absent of dyspnoea 
and anorexia); Karnofsky Performance Status; clinical prediction of survival (>12, 11–
12, 7–10, 5–6, 3–4, and 1–2 weeks); and laboratory findings (leucocyte count and 
lymphocyte percentage)[6]. 
 
SAP models 
SAP models are used to predict death within 1–6 months for cancer patients on 
chemotherapy[20]. Scores were calculated from data on the neutrophil count, lactate 
dehydrogenase, and albumin. The regression equation corresponding to each prediction 
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period was p=1/(1+exp(–CAlb×Alb– CAlb –CLDH×LDH–CNeutrophil×Neutrophil–const.)) 
 
Statistical analysis  
Comparison of patient background factors was performed by using the Student t-test, 
chi-square test, or log-rank test, as appropriate. We used the FP modelling method to 
predict the survival time (in days) from enrolment to death. FP modelling is an 
alternative to standard polynomial regression models and provides more flexible 
parameterization based on fractional polynomial functions[25]. All 17 variables were 
entered into the initial FP model: heart rate, respiratory rate, leukocyte count, 
neutrophil count, lymphocyte count, platelet count, urea, creatinine, alanine 
aminotransferase, alkaline phosphatase, total bilirubin, lactate dehydrogenase, albumin, 
C-reactive protein, NLR, PNI, and PLR. Then, we conducted 10-fold cross validation to 
correct for over-optimism in development of the models and identified the model with the 
best predictive accuracy for each target survival period.  
FP modelling differs from regular polynomials in that logarithms and noninteger powers 
can be employed, and powers can also be repeated. We used the degree-2 fractional 
polynomial of x for regression. The FP modelling technique employed the equation 
Y=β0+β1X(p1)+β2X(p2), where p1, and p2 are exponent powers selected from among {-2, -1, 
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-0.5, 0, 0.5, 1, 2, and 3}, with the model showing the best fit being chosen. The convention 
is that X0 equals LN(X)[26,27]. 
We also estimated the probability of survival using various prognostic models, i.e., the 
FP, PiPS-B 14/56, PaP, and SAP models, by calculating the AUC values. Using three 
patients extracted from the database, the survival times targeted by each model at the 
time of development were compared, i.e., 14-day survival for the PiPS-B 14 model, 30-
day survival for the PaP model, 30/56/90-day survival for the SAP models, and 56-day 
survival for the PiPS-B 56 model. All analyses were carried out using SAS software (ver. 
9.4) and R software (ver. 3.4.4), and p <0.05 was considered significant. 
 
Results 
Participants  
A total of 2426 subjects were recruited in the original study. Among them, 1387 patients 
were excluded because of missing data (date of death, laboratory findings, or vital signs), 
and we analyzed the remaining 1039 patients for this study. Patient characteristics are 
summarized in Table 1. The mean age of the patients was 67.7 years, and lung cancer 
was the most frequent primary cancer, followed by cancer of the stomach/esophagus. The 
median survival time was 33 days. Among the patients analyzed, 24.9% and 5.6% were 
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receiving chemotherapy and/or radiotherapy, respectively. Patient background factors 
including survival periods were largely consistent between the analyzed and non-
analyzed patients (Appendix 1), except that the analyzed patients were significantly 
younger, showed male predominance, had more metastatic tumors, and more 
chemotherapy. Laboratory findings are summarized in Table 2. 
 
FP models and performance 
 Table 3 summarizes the best FP models for predicting 7-day, 14-day, 30-day, 56-day, and 
90-day survival. We designated each of these models as an OPI-AC. All indexes included 
heart rate, urea, and albumin. In addition, the respiratory rate, creatinine, C-reactive 
protein, lymphocyte count, neutrophil count, total bilirubin, lactate dehydrogenase, and 
PLR were included in some indexes. The AUC values of these OPI-AC models exceeded 
0.89 for prediction of 30-day to 90-day survival, while the AUC was 0.77 for 7-day 
survival and 0.81 for 14-day survival (Table 3). Accuracy of the OPI-AC was better than 
the PiPS-B 56 model (0.89 vs. 0.83), the PaP model (0.89 vs. 0.87), and all three SAP 
models (0.89-0.92 vs. 0.74-0.82).  
 
Examples of using OPI-AC (Figure 1,2,3)  
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We calculated the estimated probability of survival for three patients using all of the 
OPI-AC models. Patient A died 10 days after enrolment, and the largest change in the 
estimated probability of survival was noted between 7 and 14 days (Figure 1). Similarly, 
the largest change was seen between 14 and 30 days for patient B who died 27 days 
after enrolment (Figure 2). Patient C died 53 days after enrolment, and the second 
largest change in the estimated probability of survival was noted between 30 and 56 
days for this patient (Figure 3).  
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Discussion 
Prediction of patient survival with minimum bias is challenging. In this study, we 
demonstrated that the prognostic prediction model using only objective data (i.e., routine 
laboratory findings and vital signs) showed high accuracy than existing predication tools 
requiring direct patient assessment by physicians and health care professionals.  
 
The most important finding of this study was that the OPI-AC models for relatively 
longer survival (30-90 days) were more accurate than existing predictive models that 
include subjective patient factors and physician evaluation. That is, the AUC for the 30-
day OPI-AC was 0.89, while the AUC for the PaP score was 0.87 in this dataset and 0.72 
in the original study[8]. Similarly, the AUC for the 56-day OPI-AC was 0.90, while the 
AUC for the PiPS-B 56 model was 0.83 in this dataset and 0.81 in the original study[7]. 
These findings indicate that prediction of survival by FP modelling is sufficiently 
accurate, even when based entirely on objective variables (i.e., laboratory findings and 
vital signs) without data from direct examination of the patient by a physician or other 
healthcare professional. 
Furthermore, the AUC for the 90-day OPI-AC was larger than that for the SAP model, 
a linear model incorporating 3 laboratory parameters that was developed from a large 
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prospective cohort database accumulated at a single centre[20]. AUC values for the 30-
day, 56-day, and 90-day OPI-AC were 0.89, 0.90, and 0.92, respectively. In contrast, the 
AUC values for the 1-month, 2-month, and 3-month SAP models were respectively 0.74, 
0.77, and 0.82 in the present study, or 0.74, 0.70, and 0.71 in the original reports[20]. 
These results indicate that addition of more variables and use of converted variables can 
contribute to improvement of predictive accuracy. 
However, the OPI-AC showed relatively lower accuracy for predicting short-term 
survival, with the AUC values of the 7-day and 14-day OPI-AC being were 0.77 and 0.81 
respectively. Among the other models, the AUC for prediction of 7-day survival using the 
OPPS was 0.82 (0.75-0.89) in a Korean study[19], while the AUC for prediction of 14-day 
survival using the PiPS-B14 was 0.86 (0.84-0.89)[7]. One possible reason is that the 7-
day and 14-day OPI-AC did not include sodium, which might be sensitive marker of 
impending death,[13] so addition of sodium could contribute to improving the predictive 
power[13]. Another possible reason is that relatively small number of patients who died 
in period of 7-days, 14-days might lead to instability of constructed prediction models. A 
more likely interpretation is that prediction of impending death is improved by assessing 
changes of vital signs and physical findings, such as drooping of the nasolabial fold, 
respiration with mandibular movement, or the death rattle[15–17]. These findings 
20 
suggest that further investigation of indexes containing more variables or daily changes 
of variables is required to determine whether relatively short-term survival can be 
predicted from objective data alone. 
Regarding clinical practice, the OPI-AC makes it possible to predict the survival of 
patients without direct involvement of physicians or other healthcare professionals. As 
previous studies have shown that physicians tend to markedly overestimate the survival 
of patients,[9,28] our models could be useful to improve the conversation among patients, 
families, and physicians regarding preparation for end-of-life care [29,30].  
In terms of research implications, FP modelling seems to be a strong method for 
developing prognostic models. We stress the importance of the methodology itself rather 
than the details of the formula, as the formula may change when using more data or a 
different study population, but the basic methodology is widely applicable[26,27]. In 
addition, our prognostic model could be used to identify patients who are eligible for 
participation in clinical trials to minimize attrition rates. 
This study has some limitations. First, the subjects analyzed in this study were limited 
to patients who received blood test due to clinical necessity. There may be a selective bias, 
but the patient backgrounds were similar between analyzed and non-analyzed patients 
and we believe this bias would not have large influence on the results. Second, although 
21 
we conducted 10-fold cross validation in this study, no external validation was performed. 
Independent validation might add some insights for final model.  
 
Conclusions  
We used FP modelling to develop highly accurate prognostic models for patients with 
advanced cancer that exclusively employed objective variables (OPI-AC). Accurate 
objective prediction may facilitate conversations about end-of-life care, and FP modelling 
seems to be a promising method for development of other prognostic indexes in future 
research. 
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Table 1 Patients Characteristics         
 All patients (n=2426) Analyzed patients (n=1039) 
  Mean S.D. Mean S.D. 
Age (yrs) 69.1 12.8 67.7 13.1 
Heart rate (beat/minute) 85.8 16.5 85.3 16.5 
Respiratory rate (breath/minute) 16.0  4.5 15.8 4.4 
 N % N % 
Male sex 1387 57.2  627 60.3  
Site of primary cancer     
Lung 519 21.4  259 24.9 
Stomach/oesophagus 326 13.4  144 13.9 
    Colon/rectum/small intestine 293 12.1  125 12.0 
Pancreas 250 10.3  111 10.7 
Liver/Biliary system 221 9.1  90 8.7 
Ovary/uterus 139 5.7  57 5.5 
Kidney/renal pelvis/ureter/bladder/prostate 162 6.7  53 5.1 
Breast 122 5.0  51 4.9 
Head and neck 78 3.2  37 3.6 
Others 258 10.6  112 10.8 
Metastatic site     
Anywhere 1927 79.4  855 82.3 
Liver 855 35.2  403 38.8 
Bone 723 29.8  308 29.6 
Lung 807 33.3  349 33.6 
Central nervous system 278 11.5  127 12.2 
Dyspnoea 700 28.9  281 27.0 
Anorexia 1813 74.7  784 75.5 
Fatigue 1712 70.6  745 71.7 
Weight loss in the previous month 1589 65.5  681 65.5 
Karnofsky Performance Scale     
  ≧50 1143 47.1  490 47.2 
  30-40 822 33.9  346 33.3 
  10-20 455 18.8  200 19.2 
ECOG-PS*1     
  0-1 255 10.5  122 11.7 
2 440 18.1  204 19.6 
3 882 36.4  357 34.4 
4 846 34.9  353 34.0 
Global Health     
1: extremely poor 248 10.2  106 10.2 
2  567 23.4  257 24.7 
3  814 33.6  316 30.4 
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4  443 18.3  202 19.4 
5-7: normal health 348 14.3  155 14.9 
Abbreviated Mental Test by physician-proxy ratings     
≦3 623 25.7  267 25.7 
Clinical prediction of survival (wks)     
>12 472 19.5  228 21.9 
11-12 144 5.9  66 6.4 
7-10 437 18.0  196 18.9 
5-6 300 12.4  113 10.9 
3-4 611 25.2  238 22.9 
1-2 455 18.8  196 18.9 
Anticancer treatment      
Chemotherapy  539 22.2  259 24.9 
Hormone therapy  36 1.5  14 1.3 
Radiotherapy  128 5.3  58 5.6 
Survival period     
≦7-day  334 14.1  141 14.1 
≦14-day  642 27.2  270 26.9 
≦30-day  1117 47.3  478 47.7 
≦56-day  1559 66.0  654 65.2 
≦90-day  1812 76.7  764 76.2 
Median survival (days; 25%, 75% tile) 33 (13, 84)   33 (13, 85)   
*1 ECOG-PS: Eastern Co-operative Oncology Group Performance Status    
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Table 2   Laboratory data of the analyzed patients 
 Mean S.D. 
Leukocyte count (109/L) 9.35 6.20  
Neutrophil count (109/L) 7.61 5.71 
lymphocyte count (109/L) 0.97 0.68 
Platelet count (109/L) 234.1  123.0  
Urea (mg/dL) 22.9 20.0  
Creatinine (mg/dL) 0.90  0.8 
Alanine aminotransferase (U/L) 42.0  79.6 
Alkaline phosphatase (U/L) 691.4 828.6 
Total bilirubin (mg/dL) 1.65 3.91  
Lactate dehydrogenase (U/L) 461.4 638.2 
Albumin (g/dL) 28.4 7.3 
C-reactive protein (mg/dL) 6.3 6.6 
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Table 3 Variables used in each model     
Estimated 
survival time 
OPI-AC formula*6 
AUC*1 (95% CI) 
OPI-AC PiPS*2-B model PaPs*3 model SAP*4 model 
7 days  Y=heart rate + urea + albumin 0.765 (0.658 - 0.872)    
14 days  Y=heart rate + urea + albumin + respiratory rate + creatinine + (C-reactive protein)-1 0.806 (0.720 - 0.892) 0.862 (0.837 - 0.888)   
30 days  Y=heart rate + (urea)-1+ (urea)-2 + albumin + (percentage of lymphocytes)-0.5 + (total bilirubin)-0.5 + (PLR*5)-2 0.894 (0.836 - 0.953)  0.870 (0.848 - 0.892) 0.742 (0.653 - 0.832) 
56 days  Y=heart rate + (logurea-2)+ (urea)-2 + albumin + percentage of lymphocytes + (total bilirubin)-1 + (PLR*5)3 + lactate dehydrogenase 0.897 (0.834 - 0.960) 0.827 (0.800 - 0.853)  0.769 (0.680 - 0.859) 
90 days  Y=heart rate + (logurea-2)+ (urea)-2 + albumin + neutrophil count + (total bilirubin)-0.5 + (PLR*5)-2 + lactate dehydrogenase 0.923 (0.860 - 0.986)   0.819 (0.734 - 0.904) 
*1 AUC: Area under the curve     
*2 PiPS: Prognosis in Palliative Care Study     
*3 PaPs: Palliative Prognostic Score     
*4 SAP: Set of six adaptable prognostic models     
*5 PLR: Platelet / lymphocyte ratio (platelet count divided by the lymphocyte count).     
*6 OPI-AC: Objective Prognostic Index     
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Appendix 1 Characteristics of analyzed vs. non-analyzed patients    
 Analyzed patients (n=1039) Non-analyzed patients (n=1387)  
 Mean S.D. Mean S.D. p value 
Age (yrs) 67.7 13.1 70.1 12.6 <0.001 
Heart rate (beats/minute) 85.3 16.5 86.1 16.6 0.232 
Respiratory rate (breaths/minute) 15.8 4.4 16.3 4.5 0.014 
 N % N %  
Male sex 627 60.3  760 54.8  0.007 
Site of primary tumor     0.129 
Lung 259 24.9 260 18.7  
Stomach/esophagus 144 13.9 182 13.1  
   Colon/rectum/small intestine 125 12.0 168 12.1  
Pancreas 111 10.7 139 10.0  
Liver/Biliary tract 90 8.7 131 9.4  
Ovary/uterus 57 5.5 82 5.9  
Kidney/renal pelvis/ureter/bladder/prostate 53 5.1 109 7.9  
Breast 51 4.9 71 5.1  
Head and neck 37 3.6 41 3.0  
Others 112 10.8 146 10.5  
Metastatic sites      
Multiple 855 82.3 1072 77.3 0.004 
Liver 403 38.8 452 32.6 0.003 
Bone 308 29.6 415 29.9 0.784 
Lung 349 33.6 458 33.0 0.875 
Central nervous system 127 12.2 151 10.9 0.344 
Dyspnea 281 27.0 419 30.2 0.092 
Anorexia 784 75.5 1029 74.2 0.496 
Fatigue 745 71.7 967 69.7 0.301 
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Weight loss in the previous month 681 65.5 908 65.5 0.877 
Karnofsky Performance Scale     0.811 
  50 490 47.2 653 47.1  
  30-40 346 33.3 476 34.3  
  10-20 200 19.2 255 18.4  
ECOG-PS*1     0.064 
  0-1 122 11.7 133 9.6  
2 204 19.6 236 17.0  
3 357 34.4 525 37.9  
4 353 34.0 493 35.5  
Global Health     0.072 
1: extremely poor 106 10.2 142 10.2  
2  257 24.7 310 22.4  
3  316 30.4 498 35.9  
4  202 19.4 241 17.4  
5-7: normal health 155 14.9 193 13.9  
Abbreviated Mental Test by physician-proxy ratings      
3 267 25.7 356 25.7 0.992 
Clinical prediction of survival (wks)     0.015 
>12 228 21.9 244 17.6  
11-12 66 6.4 78 5.6  
7-10 196 18.9 241 17.4  
5-6 113 10.9 187 13.5  
3-4 238 22.9 373 26.9  
1-2 196 18.9 259 18.7  
Anticancer therapy       
Chemotherapy  259 24.9 280 20.2 0.022 
Hormone therapy  14 1.3 22 1.6 0.563 
Radiotherapy  58 5.6 70 5.1 0.208 
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Survival period      
≦7-day  141 14.1 193 14.2 0.927 
≦14-day  270 26.9 372 27.4 0.815 
≦30-day  478 47.7 639 47.0 0.749 
≦56-day  654 65.2 905 66.5 0.497 
≦90-day  764 76.2 1048 77.1 0.614 
Median survival (days; 25%, 75%) 33 (13, 85)  34 (13, 83)   
*1 ECOG-PS: Eastern Cooperative Oncology Group Performance Status     
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Figure Legends 
 
Figure 1 
The variables for patient A were as follows: heart rate (78 beats/minute), respiratory 
rate (16 breaths/minute), neutrophil count (25.37×109/L), lymphocyte count (1.49×109/L), 
platelet count (317.0×109/L), urea (90.1 mg/dL), creatinine (1.89 mg/dL), total bilirubin 
(1.2 mg/dL), lactate dehydrogenase (343 U/L), albumin (2.4 g/dL), and C-reactive 
protein (18.3 mg/dL). 
 
Figure 2 
The variables for patient B were as follows: heart rate (86 beats/minute), respiratory 
rate (16 breaths/minute), neutrophil count (6.27×109/L), lymphocyte count (0.90×109/L), 
platelet count (106.0×109/L), urea (9.0 mg/dL), creatinine (0.54 mg/dL), total bilirubin 
(2.6 mg/dL), lactate dehydrogenase (1594 U/L), albumin (2.6 g/dL), and C-reactive 
protein (5.2 mg/dL). 
 
Figure 3 
The variables for patient C were as follows: heart rate (90 beats/minute), respiratory 
rate (15 breaths/minute), neutrophil count (8.67×109/L), lymphocyte count (0.88×109/L), 
platelet count (509.0×109/L), urea (13.0 mg/dL), creatinine (0.61 mg/dL), total bilirubin 
(1.0 mg/dL), lactate dehydrogenase (171 U/L), albumin (2.7 g/dL), and C-reactive 
protein (16.2 mg/dL). 
